Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | CYP51A1 | Q16850 | 3/20 | 0.34 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.34 |
| ▸ | QPCT | Q16769 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7585240 | 0.84 | PTGS2 (0.43) | PTGS2IDO1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7561783 | 0.84 | PTGS2 (0.43) | PTGS2IDO1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7656241 | 0.76 | CYP51A1 (0.40) | PTGS2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL7667482 | 0.75 | PTGS2 (0.43) | PTGS2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL7561794 | 0.74 | FNTA (0.40) | PTGS2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL7657941 | 0.73 | FNTA (0.37) | PTGS2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL7862159 | 0.73 | PTGS2 (0.44) | PTGS2IDO1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7660603 | 0.69 | PTGS2 (0.40) | PTGS2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL7562577 | 0.69 | FNTA (0.55) | PTGS2 | |
| SCHEMBL7563102 | 0.68 | FNTA (0.58) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | ASTRAZENECA UK LIMITED | 2002-05-02 | — | — | US | claimed |
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | ASTRAZENECA UK LIMITED | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | FNTA, FNTB, RABGGTA | PTGS2 2763/4885IDO1 2367/4885CYP3A4 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.